1

2 Original Research Article

3

4

5

Hepatitis B in Pregnancy: Knowledge, Access to Screening and Vaccination in a Low-Resource Setting, Cameroon.

6

7 ABSTRACT

Background: Hepatitis B virus (HBV) infection is a global public health problem with a high
burden in Sub-Saharan Africa. This burden is more felt in the paediatric population, mother to
child transmission (MTCT) being a major mode of infection. This study sought to assess the
knowledge of pregnant women on HBV and their access to screening and vaccination.

Methods: A cross-sectional study was carried out in the South West Region, Cameroon from 13 15th January to the 15th April, 2018 involving third trimester pregnant women attending 14 antenatal care (ANC) and those in the post-partum period admitted at the maternity wards of 15 some hospitals. Data was collected using a structured questionnaire and analyzed using SPSS 16 version 23. Knowledge was evaluated using a series of twelve questions. Vaccination status 17 was determined from vaccination cards and ANC registers.

Results: Of the 349 women studied, 31.8% were knowledgeable with scores of $\geq 6/12$. High educational level (P= 0.002) and occupation as a health worker (P < .001) were associated with good knowledge. Ninety (90.0%) had been screened for hepatitis B surface antigen (HBsAg) during pregnancy while 14.6% had been vaccinated. Determinants of vaccination were monthly income >60.000FCFA (OR: 5.7 CI: 1.6-19.9), urban residence (OR: 4.0 CI: 1.1-15.0) and regional level of ANC health facility (OR: 12.4 CI: 2.0-76.4). Conclusion: Only about three in ten women were knowledgeable on HBV infection. Ninety percent were screened during pregnancy but only ten percent were vaccinated. These results show that despite the high rate of HBV screening in this setting, most women have poor level of knowledge about this infection and its prevention. We recommend that health education on HBV should be provided to pregnant women especially during antenatal visits and that preventive measures be re-enforced in South West Region.

30 Key words: Hepatitis B, Pregnancy, Prevalence, Determinants, Access, screening,
31 vaccination, Cameroon.

- 32
- 33 1. INTRODUCTION

Infection with Hepatitis B virus (HBV) is a major public health problem worldwide. Burdens of 34 the disease are mainly in WHO Western Pacific Region and WHO African Region where 6.2% 35 and 6.1% of the adult population is infected respectively [1]. Approximately 2 billion persons are 36 37 infected worldwide of which 240 million are chronic carriers of hepatitis B virus (HBV) virus [2]. It is an important cause of morbidity and mortality and approximately 800.000 infected persons 38 die yearly of complications of chronic hepatitis mainly liver cirrhosis and hepatocellular 39 40 carcinoma (HCC) [2]. Sub-Saharan Africa is described as an area of high endemicity with an average prevalence above 8% [1,3]. Few studies in Cameroon have reported the prevalence of 41 HBV in different sub-populations as 11.9%, 19.9% and 7.7% in the general population, among 42 children, and among pregnant women respectively [4-6]. A more recent study at Buea health 43 district showed a prevalence of 9.7% in pregnant women [7]. These results place Cameroon at a 44 45 high endemicity for HBV infection (> 8% prevalence) and reveal that the disease burden in Cameroon is in the pediatric population [1,5,8]. 46

47 Mother-to-child-transmission (MTCT) is a major mode of HBV transmission worldwide, which is
48 problematic since around 90% of infected infants progress to chronic hepatitis B. This risk is much

higher than from horizontal transmission where the rate of chronicity is 30-50% when infected 49 before 6 years of age and <5% when infected in adulthood [1,9,10]. Perinatal transmission being 50 one of the commonest route of transmission, prevention of MTCT is therefore an essential step in 51 reducing the burden of disease [11,12]. For this reason, routine screening of all pregnant women 52 for hepatitis B surface antigen in each pregnancy, introduction of hepatitis B vaccine into the 53 expanded program on immunization (adopted in 2005 in Cameroon) as well as neonatal HBV 54 55 immunoprophylaxis at birth and vaccination of pregnant women at high risk of HBV is recommended [13–16]. Despite all these measures put in place, the prevalence of hepatitis B in 56 57 Cameroon as a whole, and in Cameroonian pregnant women remains high with a prevalence of 7.7% in 2013 similar to 7.85% in a study done on samples collected ten years earlier [4,17]. 58

Hepatitis B vaccine is the most effective measure for preventing HBV infection. After receiving all three doses, it provides a greater than 90% protection when received before being exposed[1,20]. This vaccine is not contraindicated in pregnancy and is safe both for the mother and fetus when administered at any of the three trimesters of gestation [21,22]. A meta-analytic study in Iranian pregnant women, 2017 estimated the HBV vaccination coverage at 9.8% [23]. In China coverage was estimated at 33% in pregnant women [24]. In Cameroon, a vaccination coverage of 2.7% was reported by Fomulu *et al* in 2012.

Several studies have assessed the prevalence of hepatitis B in pregnancy as well as the risk factors in Cameroon [4,7,25–27]. Hepatitis B vaccination in pregnancy is not one of the recommended vaccines during antenatal care (ANC) in Cameroon. However, it is fast becoming a standard of care in some health institutions because of its proven efficacy in the prevention of MTCT of hepatitis B. Despite this proven safety and protective effect of the vaccine, there is a paucity of data about the vaccination coverage in pregnant women in Cameroon. This study sought to assess the knowledge of pregnant women on HBV and their access to screening and vaccination.

73

2. MATERIALS AND METHODS

74 2.1 Study Design, Study Setting and Enrollment of Participants

This cross-sectional study was conducted at the antenatal clinics of three facilities in the southwest region (Buea, Limbe, Kumba) from 15th January to the 15th April, 2018. Two centres were selected from the secondary and one in the primary level of healthcare based on their high antenatal care client turnout. The study sites were the District Hospital Kumba (primary); the Buea and Limbe Regional Hospitals (secondary).

The study population included pregnant women in the third trimester attending antenatal clinics and women in the postpartum period admitted at the maternity ward in each of the selected centres. These women were informed about the study and requested to sign a written consent if they understood goals, procedures and accepted to participate in the study. Women in the first and second trimester and those who had never attended antenatal care for the ongoing pregnancy were excluded.

86 2.1 Sample Size Calculation and Sampling

The minimum sample size was calculated using the LORENZ formula [28]. The HBV prevalence used was 20.4% reported by Ducancelle et al, 2013 [26]. A minimum sample size of 271 was obtained with a 95% confidence and 5% accuracy and considering a 10% non-respondent rate. This sample size was then divided into the three hospitals according to their antenatal care turnout (BRH= 50 ANC clients/month giving a sample of 76 women; LRH= 60 ANC clients/month giving a sample of 90 women; DHK= 70 ANC clients/month giving a sample of 105 women). The study participants were chosen by convenience sampling.

94

95 **2.2 Data Collection**

A structured interviewer-administered questionnaire was used to collect data for both literate and 97 illiterate women in the language they best understood. The questionnaire contained questions about 98 socio-demographic characteristics. Questions to evaluate the level of knowledge of pregnant 99 women about Hepatitis B virus infection, their access to screening and vaccination were equally 100 asked. Prior to the use of the questionnaire in study participants, the questionnaire was pretested 101 in 30 pregnant women with the aim of revising poorly structured questions, estimate the average 102 103 time required to fill the questionnaire and thus validate the use of the questionnaire in our context. Information retrieved from pre-test group was not included in the final analysis. After data 104 105 collection, the data were entered into CS Pro and then exported to SPSS version 23 for analysis.

106

107 **2.3 Data Analysis**

Knowledge was assessed by computing the number of correct responses to 12general knowledge 108 questions on Hepatitis B and scored. For each correct answer, a score of one (1) was allocated, 109 while the score of zero (0) was allocated for no answer and for incorrect answers. Scores were 110 stratified into four levels based on Essi and Njoya's2013 guide on assessment of knowledge in 111 112 KAP studies (Poor knowledge was considered for respondents with a total score of <3 marks(less than 25% right answers); insufficient knowledge for scores ranging from 3 to5 (25 to 49% of right 113 answers), average knowledge for scores ranging from 6 and 8(50 to 69% of right answers) and 114 115 adequate knowledge for scores >8 (>70% of right answers) [29]. The vaccination status was based on the vaccination card and ANC registers, in the absence of which the participant's recall was 116 used. All women who had a documentation of administration of at least a dose of hepatitis B 117 118 Vaccine were considered "vaccinated"; those who had received at least three doses of the vaccine were considered "completely vaccinated" while those who had not completed their vaccination 119 schedule were considered "incompletely vaccinated". Participants who had never received a dose 120

of Hepatitis B vaccine were considered "not vaccinated". The screening status was based on the 121 documentation of HBsAg testing during the previous ANC sessions for the ongoing pregnancy. 122

Data was analysed with the Statistical Package for Social Sciences (SPSS) software version 23; 123 frequency tables were created for proportions, Chi-square test for associations between categorical 124 variables and one-way analysis of variance (ANOVA) for comparison of means between groups. 125 126 Significant variables from cross tabulation between knowledge, screening vaccination status and sociodemographic variables were inserted into a binary logistic regression model. A p-value of 127 <0.05 was considered statistically significant. 128

129

3. RESULTS

Out of a total of 353 potential participants who were approached for the study, 349 women were 130 recruited. Of these, 93 (26.6%) and 114 (32.7%) were enrolled at the Buea and Limbe Regional 131 Hospitals respectively (secondary centres); while 142 (40.7%) were enrolled at the District Hospital 132 Kumba (Primary centre). Four potential participants did not consent for personal reasons, giving a 133 response rate of 98.9%. The ages of the participants ranged from 16 to 43 years with a mean age 134 of 27.35 ± 5.18 years in the general population. Majority were married or cohabiting 234 (67%) 135 while 115 (33%) were single. More than half 55 (58.5%) had < 60000 FCFA as monthly income 136 because the majority of the participants refused to disclose their income. The study included 191 137 (54.7%) pregnant women and 158 (45.3%) women in the post-partum period. All pregnant 138 participants were in the third trimester with gestational ages (weeks) ranging from 28 to 41weeks 139 and a mean of 32.2 ± 4.1 weeks. Significant differences between participants in the different health 140 facilities were found in age, residence and gravidity. Table 1 summaries the socio-demographic 141 142 and obstetric characteristics of the respondents.

143

Table 1. Socio-demographic characteristics of participants in the various centres 144

145	
	Variables

Variables	BR	Η		LRH	I	OHK	ΤΟΤΑ	L	p-value
-	n	%	n	%	n	%	n	%	•
Age									
<20	7	7.5	4	3.5	7	4.9	18	5.2	
20 < 25	28	28.6	27	23.7	36	25.4	91	26.1	
25 < 30	35	37.6	39	34.2	48	33.8	122	35.0	
30 < 35	21	22.6	37	32.4	38	26.7	96	27.5	0.004
>35	2	2.2	7	6.1	13	9.2	22	6.3	
Total	93	100	114	100	142	100	349	100	
Residence									
Urban	62	66.7	78	68.4	61	43.0	201	57.6	
Rural	31	33.3	36	31.6	81	57.0	148	42.4	0.000
Total	93	100	114	100	142	100	349	100	
Marital status									
Single	35	37.6	29	25.4	51	35.9	115	33.0	
Married	58	62.4	85	74.6	91	64.1	234	67.0	0.111
Total	93	100	114	100	142	100	349	100	
Income level									
<60.000fcfa	11	45.8	21	44.7	7	30.4	39	41.5	
>60.000fcfa	13	54.2	26	55.3	16	69.6	55	58.5	0.463
Total	24	100	47	100	23	100	94	100	
Gravidity									
1	47	50.5	38	33.3	39	27.5	124	35.5	
2-4	42	45.2	62	54.3	88	62.0	192	55.0	
≥5	4	4.3	14	12.2	15	10.6	33	9.5	0.004
Total	93	100	114	100	142	100	349	100	

On the assessment of knowledge, 195 (55.9%) of participants had a poor knowledge about HBV
infection, MTCT of HBV and HBV vaccination with knowledge scores <3. Only 74 (21.2%) of

150 participants had good knowledge (knowledge score ≥ 8). Table 2 summarizes the knowledge of

151 study participants on Hepatitis B.

152

153 Table 2. Knowledge, screening and vaccination status of the participants.

154

Variables	Frequency (n= 349)	Percentage (%)
Knowledge		
Good (score ≥8)	74	21.2
Average (score 6-7)	37	10.6
Insufficient (score 3-5)	43	12.3
Poor (score <3)	195	55.9
Previously screened		
Yes	314	90.0
No	35	10.0
Previously Vaccinated*		
Yes		
Completed (3 doses)	9	10.9
Incomplete	38	1.1
respecting schedule	4	10.9
Incomplete not		
respecting schedule	51	14.6
Total		
No	298	85.4

155

156 *Vaccination status was based on participant's recall (3.9%) and vaccination cards (96.1%).

157

Knowledge about HBV was obtained from various sources; among all respondents, common
sources included counseling sessions (79.5%), discussions with relatives and friends (27.3%) and
the media (16.9%).

161 As shown in Table 2, 314 (90.0%) respondents had previously been screened for HBV infection

during the ongoing pregnancy, and 51 (14.6%) had received at least one dose of hepatitis B vaccine.

Only 9 (2.6%) were completely vaccinated. Thirty-eight (10.9%) were incompletely vaccinated but were following their normal vaccination schedule while 4 (1.1%) were incompletely vaccinated and had missed their subsequent doses by more than two years. An evaluation of associations between knowledge, previous screening and vaccination with sociodemographic variables was done using cross tabulation and significant variables were entered into a binary logistic regression model (Tables3 to 6).

169 Following a univariate analysis, health workers (OR: 0.9 CI: 0.9-1.0), respondents attending ANC

in a regional hospital (OR: 3.4 CI: 3.0- 5.4) and respondents with more than primary level of

education (OR: 0.1 CI: 0.0- 0.4) were more likely to have good knowledge p-values = 0.002, 0.000

and 0.000 respectively (Table 3). However, on multivariate analysis none of the factors were found

to be predictors of good knowledge (Table 4). The tables 3 to 6 show predictors of good knowledge,

screening and vaccination in the respondents.

175

173

Variables	Knowledge level		Odds ratio	Confidence p-value interval	
	Good	Not good			
Age					
<35	67(20.5%)	260(79.5%)	0.6	0.2-1.4	0.277
>35	7(31.8%)	15(68.2%)			
Occupation					
Health worker	4(100%)	0(0.0%)	0.9	0.9-1.0	0.002
Not health worker	70(20.3%)	275(79.7%)			
Level of Education					
≤ Primary	2(3.6%)	54(96.4%)	0.1	0.0-0.4	0.000
> Primary	72(24.6%)	221(75.4%)			
ANC hospital					
Secondary	47(33.3%)	94(66.6%)	3.4	2.0- 5.7	0.000
Primary	27(13.0%)	181(87.0%)			

176 Table 3. Factors associated with good knowledge on Hepatitis B.

177

178

Table 4. Predictors of good level of knowledge on Hepatitis B.

Variables	Good knowledge	AOR(Confidence Interval)	A p-value
Age		-	
<35	67(20.5%)	0.3(0.6-1.4)	0.254
>35	7(31.8%)		
Occupation			
Health worker	4(100%)	0.3(0.0-2.1)	0.999
Not health worker	70(20.3%)		
Level of education			
≤ Primary	2(3.6%)	0.3(0.03-2.2)	0.218
>primary	72(24.6%)		
ANC hospital			
Regional	47(33.3%)	2.5(0.8-8.0)	0.113
Peripheral	27(13.0%)	`````	

Table 5. Predictors of Screening for Hepatitis B.

Variables	Previous screening (yes)	AOR (Confidence Interval)	A p-value
Age			
<35	279(90.3%)	0.5(0.06- 5.0)	0.577
>35	20(90.9)	1	
Occupation			
≤60.000FCFA	247(89.8%)	1	
>60.000FCFA	70(94.6%)	1.0(0.2-5.7)	0.961
Level of education			
≤ Primary	48(85.7%)	0.5(0.1-2.4)	0.376
>primary	269(91.8%)	1	
ANC hospital			
Regional	136(96.5%)	5.6(1.1-28.4)	0.036
Primary	181(87.0%)	1	

192

193

194

195 Table 6. Predictors of HBV vaccination.

196

Variable	N (%)	AOR (95% CI)	p- value
Knowledge			
Good knowledge	25(32.5)	2.6(0.8-9.1)	0.124
Poor knowledge	52(67.5)	1	
ANC health facility			
Regional hosp.	48(62.3)	12.4(2.0-76.4)	0.007
Primary.	29(37.7)	1	
State of client			
Pregnant	49(63.6)	2.4(0.5-11.5)	0.261
Post-partum	28(36.4)	1	
Residence			
Urban	45(58.4)	4.0(1.1-15.0)	0.037
Rural	32(41.6)	1	
Monthly income	``'		
>60000	34(44.2)	5.7(1.6-19.9)	0.007
<60000	43(55.8)	1	

197

198

Pregnant women attending ANC at the regional hospitals were more likely to have been screened during the ongoing pregnancy (OR: 5.6, CI: 1.1-28.4, p=0.036) and vaccinated than their counterparts (AOR 12.4(2.0-76.4) p=0.007). Furthermore, those living in urban areas (p=0.037) and those with a monthly income of greater than 60.000FCFA (p=0.007) were more likely to have been vaccinated. However, a good knowledge on HBV infection was not significantly associated with HBV vaccination (Table 6).

205 **4. DISCUSSION**

Limiting Mother to child transmission of HBV infection has been identified as the main axis of care in order to envisage eradication of HBV infection worldwide. Screening asymptomatic people is an important instrument of disease detection, diagnosis and intervention but also a means of detecting candidates eligible for vaccination. Given that infected pregnant women stand the chance of transmitting the HBV infection to their newborn babies, we decided to conduct a cross-sectional
study to determine what proportion of pregnant women attending ANC in Buea are knowledgeable,
screened and/ or vaccinated during pregnancy to limit MTCT of HBV in the southwest region. The
information gathered from this piece of work will be used by the health care providers in the region
to scale up their current practices as concerns PMTCT of HBV infection.

In the current study, the predominant age group of the respondents was 25<30years. This is similar to the results of Adeyemi *et al*, Nigeria 2013 who described a predominant age group of 26-35 years which is within the reproductive age bracket and this emphasizes the need for preventive measures in all women of childbearing age [30].

219 In our study, 31.8% of women had at least an average level of knowledge while up to 55.9% had a poor knowledge on HBV infection. Good knowledge about HBV was found to be more likely 220 in women who attended antenatal care at the secondary level of healthcare, those with higher levels 221 of education and in health workers. The two latter may be due to their relatively higher exposure 222 223 to the healthcare services and information on HBV infection. Good level of knowledge was associated with attending ANC in a higher health care level on the other hand could be due to 224 increase standards of care probably attributable to the greater number of specialists who have been 225 shown (Paulet al, Cameroon, 2017) to have a relatively higher level of knowledge on HBV 226 infection as opposed to other health care workers [31]. 227

The results also reveal a high rate of HBsAg screening of pregnant women with a 90% screening rate. This result is similar to the findings of Walker et al in the USA; 2016 who had reported a screening rate of 98.5% [32]. It is however higher than the 8.5% reported by Adeyemi et al 2013, Nigeria. [30] This may be due to the relatively higher proportion of health practitioners in Cameroon who have incorporated HBsAg screening into the routine ANC as compared to those in Nigeria. The vaccination rate of 14.6% for at least a dose of HBV vaccine was the highest reported nationwide [4, 25, 33]. This may be due to adoption of maternal HBV vaccination of non-infected pregnant women in some of our study areas. The result is however lower than the 33% reported by Chan et al in China, 2009 probably due to socio-economic differences between the two settings [24].

Attending ANC at the secondary health care level was associated with higher rates of screening and vaccination probably due to increased standard of care as compared to the primary level. Living in an urban residence and having a higher monthly income were significantly associated with a higher vaccination rate probably related to the relatively easier accessibility to health care and also to information on the disease and its prevention via the media as supported by their relatively higher Knowledge on HBV earlier stated.

These findings may mean that vaccination is poor among pregnant women in our society and that more effort needs to be directed towards instituting guidelines and well-structured protocols for these services in adults.

2485. CONCLUSION

249 Only about three in ten women were knowledgeable on HBV infection. Ninety percent were screened during pregnancy but only ten percent were vaccinated. High vaccination rates were 250 associated with; antenatal care provided at the secondary health care level, good knowledge, 251 screening, urban residence and high monthly income. These results show that despite the high 252 rate of HBV screening in this setting, most women have poor level of knowledge about this 253 infection and its prevention. We recommend that health education on HBV should be provided 254 255 to pregnant women especially during antenatal visits and that preventive measures be reenforced in our setting. 256

257 **Limitations of Study**

The assessment of level of knowledge of the participants on hepatitis was not exhaustive using 258 twelve questions but these questions were selected in such a way that they suited the study 259 objectives and a scoring system ensure objectivity, reproducibility and reliability. Information on 260 the vaccination status was obtained from the participants so there was a risk of recall bias, however 261 this was reduced by the fact that most of them (96 %) had vaccination cards. By selecting high 262 volume centers providing both first and second levels of health care in the region, it permitted 263 264 generalization of the findings which is a limitation of the study. Despite these limitations, this study addressed issues on Hepatitis B in pregnancy in a country where routine screening and vaccination 265 266 have not been instituted as a national policy

267 **Declarations:**

268 Ethics Approval and Consent to Participate

Ethical clearance was obtained from the Faculty of Health Sciences Institutional Review Board of the University of Buea (N^O 2018/128/UB/SG/IRB/FHS) and administrative authorization from the Regional Delegation of Public Health for the South West Region of Cameroon. Participants had the study protocol carefully explained to them and participation was voluntary. Written informed consent was obtained from all participants. All procedures were standard involving minimum risks.

275 **Consent for publication**

276 Not applicable

277 Availability of data and materials

The data sets supporting conclusion of this study are available from the corresponding authorupon reasonable request.

280

281 List of abbreviations;

- ANC: Antenatal care; CI: Confidence interval; HBsAg: Hepatitis B surface antigen; HBV:
- Hepatitis B virus; **MTCT**: Mother to Child Transmission; **WHO**: World Health Organization.
- 284
- 285

286	References
287	1.World Health Organization. WHO hepatitis B. Geneva: WHO; 2017. Available from:
288	http://www.who.int/mediacentre/factsheets/fs204/en/.
289	2. Lavanchy D, Kane M. Global Epidemiology of Hepatitis B Virus Infection [Internet]. 2016.
290	p. 187–203.
291	3. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B
292	virus burden in developing countries. World J Gastroenterol. 2015;21(42):11941–53.
293	4. Fomulu NJ, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence, correlates
294	and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal
295	transmission of HBV neglected in Cameroon? BMC Pregnancy Childbirth. 2013;13(1):158.
296	5. Chiaramonte M, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, Kaptue L, et al.
297	Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J
298	Med Virol. 1991;33(2):95–9.
299	6. Infectious Diseases of Cameroon: GIDEON Informatics, Google Books [Internet].
300	Cameroon: 2017 edition. Available from: https://www.gideononline.com/ebooks/disease.
301	7. Frambo AAB, Atashili J, Fon PN, Ndumbe PM. Prevalence of HBsAg and knowledge
302	about hepatitis B in pregnancy in the Buea Health District, Cameroon: a cross-sectional study.
303	BMC Res Notes. 2014;7(1):394.
304	8. Ndumbe PM, Njie TK. Hepatitis A and B infections in yaoundé, Cameroon. Res Virol.
305	1989; 140:253–61.
306	9. Gambarin-Gelwan M. Hepatitis B in Pregnancy. Clin Liver Dis. 2007;11(4):945–63.
307	10.Lai CL, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. The Lancet. 2003
308	;362(9401):2089–94.
309	11. Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, Poustchi H. Hepatitis B virus

310 infection during pregnancy: transmission and prevention. Middle East J Dig Dis. 2011;3(2):92.

311	12. Han Z, Yin Y, Zhang Y, Ehrhardt S, Thio CL, Nelson KE, et al. Knowledge of and attitudes
312	towards hepatitis B and its transmission from mother to child among pregnant women in
313	Guangdong Province, China. PLoS ONE [. 2017; 12(6).
314	13. Ayoub WS, Cohen E. Hepatitis B management in the pregnant patient: an update. J Clin
315	TranslHepatol. 2016;4(3):241.
316	14. UNICEF. Cameroon: WHO and UNICEF estimates of immunization coverage: 2016
317	revision. UNICEF; 2016. Available from: https://data.unicef.org/wp-
318	content/uploads/country_profiles/Cameroon/immunization_country_profiles/immunization_cmr.
319	15. Expanded programme on immunization. Global Advisory GroupPart I. Releve Epidemiol
320	Hebd. 1992;67(3):11–5.
321	16. Kane MA. Global status of hepatitis B immunisation. Lancet Lond Engl. 1996 14;
322	<mark>348(9029):696.</mark>
323	17. Kfutwah AKW, Tejiokem MC, Njouom R.A low proportion of HBeAg among
324	HBsAg-positive pregnant women with known HIV status could suggest low perinatal
325	transmission of HBV in Cameroon Virology Journal. 2012; 9 (62)
326	18. Nelson NP, Jamieson DJ, Murphy TV. Prevention of Perinatal Hepatitis B Virus
520	
327	Transmission. J Pediatr Infect Dis Soc. 2014; 3 Suppl 1: S7–12.
328	19. Knoema. Cameroun Taux de fertilité.Cameroon: 2017 Knoema Available from:
329	https://knoema.fr//atlas/Cameroun/topics/Données-démographiques/Fertilité/Taux-de-fertilité.
330	20. Centers for Disease Control and Prevention. HBV FAQs for Health
331	Professionals [Internet]. USA: CDC; 2016. Available from:
332	https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm.
333	21. Centers for Disease Control and Prevention. Hepatitis B Vaccine Safety Vaccines
334	[Internet]. USA: CDC; 2015.
335	Available from https://www.cdc.gov/vaccinesafety/vaccines/hepatitis-b-vaccine.html
336	22. Ayoola EA, Johnson AOK. Hepatitis B vaccine in pregnancy: Immunogenicity, safety and
337	transfer of antibodies to infants. Int J Gynecol Obstet. 1987 Aug 1;25(4):297–301.
338	23. Badfar G, Shohani M, Nasirkandy MP, Mansouri A, Abangah G, Rahmati S, et al.
339	Epidemiology of hepatitis B in pregnant Iranian women: a systematic review and meta-analysis.
340	Arch Virol. 2017; PMID: 29063378

341	24. Chan OK, Suen SSH, Lao TT-H, Leung VKT, Yeung SW, Leung TY. Determinants of
342	hepatitis B vaccine uptake among pregnant Chinese women in Hong Kong. Int J Gynecol Amp
343	Obstet. 106:232–5.
344	25. Noubiap JJN, Nansseu JRN, Ndoula ST, Bigna JJR, Jingi AM, Fokom-Domgue J.
345	Prevalence, infectivity and correlates of hepatitis B virus infection. 2015;15(1).
346	26. Ducancelle A, Abgueguen P, Birguel J, Mansour W, Pivert A, Le Guillou-Guillemette H,
347	et al. High Endemicity and Low Molecular Diversity of Hepatitis B Virus Infections in Pregnant
348	Women in a Rural District of North Cameroon. PLOS ONE. 2013; 8 (11).
349	27. PL026.Burden of Hepatitis B virus and the risk of vertical Transmission at the Penka
350	Michel Health District.Cameroon:PL026; Mar2017. Available from: http://www.masante-
351	cam.org /273.
352	28. Charan J, Biswas T. How to Calculate Sample Size for Different Study Designs in
353	Medical Research? Indian J Psychol Med. 2013;35(2):121–6.
354	
355	29.Essi MJ, Njoya O. L'Enquête CAP (Connaissances, Attitudes, Pratiques) en Recherche
356	Médicale. Laboratoire de Recherche sur les Hépatites Virales et Communication en Santé-
357	FMSB.Health Sci. Di.2013; 14(2).
358	30. Adeyemi AB, Enabor OO, Ugwu IA, Bello FA, Olayemi OO. Knowledge of hepatitis B
359	virus infection, access to screening and vaccination among pregnant women in Ibadan, Nigeria. J
360	ObstetGynaecol J Inst ObstetGynaecol. 2013;33(2):155–9.
361	31. Paul T, Marie TP, Bechem E. Knowledge, attitude and practice of staff of 4 hospitals in
362	Yaoundé on the prevention of vertical transmission of hepatitis B. Pan Afr Med J. 2017 25;28(174).
363	32. Walker TY, Smith EA, Fenlon N, Lazaroff JE, Dusek C, Fineis P, et al. Characteristics of
364	Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012.
365	Public Health Rep. 2016;131(5):685–94.
366	33. Dionne-Odom J, Mbah R, Rembert NJ, Tancho S, Halle-Ekane GE, Enah C et al. Hepatitis
367	B, HIV, and Syphilis Seroprevalence in Pregnant Women and Blood Donors in Cameroon: a cross-
368	sectional study. Infectious Diseases in Obst and Gynecol Volume 2016.

369 DOI.org/10.1155/2016/4359401, Article ID 4359401.